CAGE Bio Initiates Phase 2 Trial of First-in-Class DNA Aptamer Therapy CGB-600 for Vitiligo Treatment
Key Insights
CAGE Bio (search) has launched a randomized, double-blind, placebo-controlled Phase 2 clinical trial evaluating CGB-600 (search), a first-in-class DNA aptamer therapy for vitiligo (search) treatment.
CGB-600 (search) specifically targets interferon gamma to downregulate autoimmune activity responsible for melanocyte destruction, potentially offering more durable re-pigmentation with fewer side effects.
The study will enroll 36 adult patients with nonsegmental facial vitiligo (search), with primary endpoints of tolerability and F-VASI score improvement at Week 24.
CAGE Bio (search) Inc., a clinical-stage biotechnology company, has initiated a Phase 2 clinical trial of CGB-600 (search), a novel topical DNA aptamer therapy for vitiligo (search) treatment. The investigational therapy represents a first-in-class approach targeting the autoimmune mechanisms underlying this challenging dermatological condition.
Novel DNA Aptamer Mechanism
CGB-600 (search), licensed from TAGCyx Biotechnologies (search) Inc. of Japan, is designed as a first-in-class DNA aptamer and new chemical entity that selectively binds to interferon gamma. By targeting this specific cytokine, the therapy aims to downregulate autoimmune activity implicated in the localized destruction of melanocytes, the pigment-producing cells affected in vitiligo (search).
"Vitiligo (search) remains an area of high unmet medical need with limited durable treatment options," said Dr. Nitin Joshi, Chief Executive Officer of CAGE Bio (search). "Our DNA Aptamer program opens an entirely new therapeutic modality in immune-targeted skin therapeutics. Prior preclinical proof-of-concept studies suggest CGB-600 (search) can achieve significant and sustained re-pigmentation. We believe this could be a transformative advancement for patients and providers."
Breakthrough in Topical Drug Delivery
The trial represents a significant advancement in drug delivery technology, particularly for large molecular therapeutics. Dr. Samir Mitragotri, Professor of Bioengineering at Harvard University, who pioneered the ionic liquid drug delivery platform, highlighted the technical achievement: "Nucleic acids are large, charged molecules and their localized, topical delivery is a huge unmet need. This human clinical trial, where a drug of this size is being delivered non-invasively into the skin, is a major advancement in the drug delivery field."
Phase 2 Trial Design and Endpoints
The randomized, double-blind, placebo-controlled study will enroll 36 adult patients with nonsegmental facial vitiligo (search). The primary endpoints focus on tolerability and improvement in F-VASI (Facial Vitiligo Area Scoring Index) score at Week 24. Top-line results are anticipated in the third quarter of 2026.
Market Context and Competitive Landscape
The global vitiligo (search) treatment market is projected to exceed $2 billion in the coming years, yet options with sustained benefits remain scarce. While recent advances with JAK inhibitors have expanded treatment possibilities for patients, CGB-600 (search) offers a differentiated approach with the potential for enhanced selectivity, lower side effects, and sustained benefits compared to existing treatments.
Company Pipeline Expansion
Beyond the vitiligo (search) program, CAGE Bio (search) has also announced a collaboration with Mayo Clinic to develop novel therapeutics for cutaneous graft-versus-host disease (search) (GvHD), a debilitating condition that remains difficult to manage. This collaboration will combine Mayo Clinic's clinical expertise with CAGE Bio's proprietary ionic liquid technology to accelerate development of new treatment options for this challenging condition.